Shankar Srinivasan, MD
Psychiatry · Parsippany, NJNPI 1093855728
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $123,883 of the $154,946 with a category attached, or 80.0%. 34 manufacturers reported payments, led by AbbVie at 52.5% of the total. 2025 is the largest year on record at $64,838, more than ten times the $2,042 reported in 2019. Among psychiatry clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 942 payments — averaging $164.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$81K
- Axsome Therapeutics, Inc.$34K
- Supernus Pharmaceuticals, Inc.$24K
- Idorsia Pharmaceuticals US Inc$8K
- Alkermes, Inc.$839
- Takeda Pharmaceuticals U.S.A., Inc.$688
- plus $5K from 28 others
What the payments were for
- Consulting fees$16,40011%
- Speaking & faculty fees$123,88380%
- Travel & lodging$2,3812%
- Food & beverage$12,2538%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$154,946 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 150 | $215,799 |
| IngrezzaValbenazine Tosylate | 16 | $121,949 |
| SpravatoEsketamine Hcl | 52 | $106,867 |
| AustedoDeutetrabenazine | 12 | $91,795 |
| RexultiBrexpiprazole | 29 | $42,962 |
| TrintellixVortioxetine Hydrobromide | 59 | $39,168 |
| Invega SustennaPaliperidone Palmitate | 12 | $28,786 |
| AdderallDextroamphetamine/Amphetamine | 32 | $22,832 |
| Lurasidone Hcl | 102 | $21,973 |
| LybalviOlanzapine/Samidorphan Malate | 14 | $21,931 |
| Aripiprazole | 230 | $21,544 |
| AuvelityDextromethorphan Hbr/Bupropion | 18 | $18,800 |
| Adderall XrDextroamphetamine/Amphetamine | 35 | $12,466 |
| XanaxAlprazolam | 12 | $10,637 |
| ProzacFluoxetine Hcl | 25 | $10,563 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $81,291 | $215,799150 claims |
| Johnson & JohnsonSpravato, Invega Sustenna | $481 | $135,65364 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $227 | $121,94916 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $346 | $91,79512 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Adderall, Vyvanse | $688 | $70,683115 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $601 | $42,96229 claims |
| Alkermes, Inc.Lybalvi | $839 | $21,93114 claims |
| Axsome Therapeutics, Inc.Auvelity | $34,182 | $18,80018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in New Jersey.
Other psychiatry in Parsippany
- Marc CantillonLivingston$522K
- Robert BransfieldRed Bank$415K
- Erika ConcepcionLong Branch$354K
- Leon RosenbergCherry Hill$257K
- Lloyd AlceraMarlton$187K
- Gary SmallHackensack$170K
- Matthew PiteraToms River$153K
- Boris BorodulinEast Brunswick$116K
- Anthony RostainCamden$110K
- Aijaz NanjianiParamus$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.